The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III study of adjuvant versus progression-triggered treatment with gemcitabine (G) after radical cystectomy (RC) for locally advanced bladder cancer (LABC) in patients not suitable for cisplatin-based chemotherapy (CBC) (AUO-trial AB22/00).
Jan Lehmann
No relevant relationships to disclose
Michael Kuehn
No relevant relationships to disclose
Claus Fischer
No relevant relationships to disclose
Bjoern Volkmer
No relevant relationships to disclose
Friedrich von Rundstedt
No relevant relationships to disclose
Peter Albers
No relevant relationships to disclose
Eduard Becht
No relevant relationships to disclose
Andreas Bannowsky
No relevant relationships to disclose
Rainer Hofmann
No relevant relationships to disclose
Sigrun Langbein
No relevant relationships to disclose
Margitta Retz
No relevant relationships to disclose
Michael Stoeckle
No relevant relationships to disclose